Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Rossi

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1990
Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parametersJ M Jacquet, F Bressolle, M Galtier, et al.
Journal of Immunological Methods|June 23, 1997
Large scale and clinical grade purification of syndecan-1+ malignant plasma cellsR X Sun, Z Y Lu, J Wijdenes, et al.
Cancer|September 15, 1988
Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myelomaC Marcelli, D Chappard, J F Rossi, et al.
Human Pathology|February 10, 2000
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimensV Costes, V Magen, E Legouffe, et al.
The European Journal of Medicine|October 1, 1992
Non-Hodgkin's lymphoma associated with primary Sjögren's syndromeD Pariente, J M Anaya, B Combe, et al.
Blood|April 16, 1998
Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirusK Tarte, S J Olsen, Z Yang Lu, et al.
British Journal of Haematology|December 1, 1990
Osteoblast stimulation in multiple myeloma lacking lytic bone lesionsR Bataille, D Chappard, C Marcelli, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Bayesian estimation of doxorubicin pharmacokinetic parametersF Bressolle, P Ray, J M Jacquet, et al.
Journal of Clinical Pathology|February 14, 1998
Expression of the interleukin 6 receptor in primary renal cell carcinomaV Costes, J Liautard, M C Picot, et al.
Leukemia|September 17, 2010
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationA C Sprynski, D Hose, A Kassambara, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|January 1, 1990
Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parametersJ M Jacquet, F Bressolle, M Galtier, et al.
Journal of Immunological Methods|June 23, 1997
Large scale and clinical grade purification of syndecan-1+ malignant plasma cellsR X Sun, Z Y Lu, J Wijdenes, et al.
Cancer|September 15, 1988
Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myelomaC Marcelli, D Chappard, J F Rossi, et al.
Human Pathology|February 10, 2000
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimensV Costes, V Magen, E Legouffe, et al.
The European Journal of Medicine|October 1, 1992
Non-Hodgkin's lymphoma associated with primary Sjögren's syndromeD Pariente, J M Anaya, B Combe, et al.
Blood|April 16, 1998
Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirusK Tarte, S J Olsen, Z Yang Lu, et al.
British Journal of Haematology|December 1, 1990
Osteoblast stimulation in multiple myeloma lacking lytic bone lesionsR Bataille, D Chappard, C Marcelli, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Bayesian estimation of doxorubicin pharmacokinetic parametersF Bressolle, P Ray, J M Jacquet, et al.
Journal of Clinical Pathology|February 14, 1998
Expression of the interleukin 6 receptor in primary renal cell carcinomaV Costes, J Liautard, M C Picot, et al.
Leukemia|September 17, 2010
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationA C Sprynski, D Hose, A Kassambara, et al.
Pageof 12